Aeterna Zentaris (AEZS) 3.49 $AEZS Aeterna Zentaris

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris (AEZS) 3.49 $AEZS

Aeterna Zentaris Announces Expiration of Remaining Series B Warrants
BusinessWire - Wed Sep 14, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the remaining 8,064 Series B Common Share Purchase Warrants (the "Series B Warrants" issued in connection with the Company's March 2015 financing expired on September 12, 2016 without being exercised. The Company had 9,939,863 Common Shares issued and outstanding as of the close of business on September 13, 2016.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris to Present at Upcoming Aegis Capital Corp. 2016 Growth Conference in Las Vegas, Nevada
BusinessWire - Mon Sep 12, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company" today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the Aegis Capital Corp. 2016 Growth Conference on Thursday, September 22, 2016 at 1:00 p.m. (Pacific Daylight Time) in Room 1, Life Science in The Encore at Wynn Las Vegas, Las Vegas, Nevada.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
BusinessWire - Tue Sep 06, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 9:35 a.m. (Eastern) in conference room Kennedy I (4th Floor) in the Lotte New York Palace Hotel in New York City.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results
BusinessWire - Tue Aug 09, 3:30PM CDT
--All $ amounts are in US Dollars
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Expands Promotion of APIFINY(R) into Florida
BusinessWire - Mon Aug 08, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that it is expanding its promotion of APIFINY(R), the only cancer-specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, into the important Florida market pursuant to its exclusive promotional agreement with Armune BioScience, Inc. ("Armune", the owner of the product. The expansion into Florida follows Armune's receipt of a clinical laboratory license from the State of Florida.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex(TM) in Israel
BusinessWire - Mon Aug 01, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company" and Rafa Laboratories, Ltd. ("Rafa" today announced the signing of an exclusive license agreement for the Company's lead anti-cancer compound, Zoptrex(TM) (zoptarelin doxorubicin), for the initial indication of endometrial cancer, for Israel and the Palestinian Territories (the "Territory". Zoptrex(TM), a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer. The Company expects to complete the Phase 3 clinical trial in the third quarter of 2016 and, if the results of the trial warrant doing so, to file a new drug application for Zoptrex(TM) in the first half of 2017.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Announces IND Submission by Sinopharm A-Think
BusinessWire - Tue Jun 14, 4:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that its licensee, Sinopharm A-Think Pharmaceuticals Co., Ltd. ("Sinopharm A-Think", which is affiliated with the largest state-owned pharmaceutical company in the People's Republic of China, today submitted an Investigational New Drug application ("IND" for Zoptrex(TM) to the Chinese State Food and Drug Administration ("CFDA", remaining on track to commence its clinical program during the first half of 2017.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting Zoptrex(TM) During 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 4:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company" today reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, phase 3 trial for Zoptrex(TM) (zoptarelin doxorubicin) in women with advanced, recurrent endometrial cancer, is expected to be completed in the third quarter of 2016. During the 2016 Annual Meeting of the American Society of Clinical Oncologists ("ASCO", the Company also discussed its plans to develop Zoptrex(TM) for additional indications, based upon achieving a positive outcome in the current clinical program.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board
BusinessWire - Mon May 23, 7:15PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company", a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today announced the separation of the positions of Chairman of the Board and President and Chief Executive Officer. Ms. Carolyn Egbert has been elected Chair of the Board, a non-executive position, by the Company's Board of Directors, and the position of Lead Director was eliminated. David A. Dodd, who has served as Chairman, President and Chief Executive Officer since 2014, will continue to serve as President and Chief Executive Officer of the Company and as a director. Mr. Juergen Ernst, the former Lead Director, will remain as a director of the Company.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting
BusinessWire - Tue May 10, 3:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company", a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today announced the results of the vote on directors held at its 2016 annual meeting of shareholders held earlier today on May 10, 2016. Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies with regard to voting on the six directors nominated for election as set forth in the table below:
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris reports 1Q loss
Automated Insights - Mon May 09, 5:26PM CDT
MONTREAL (AP) _ Aeterna Zentaris Inc. (AEZS) on Monday reported a loss of $3.7 million in its first quarter.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY(R) Prostate Cancer Blood Test
BusinessWire - Wed Apr 27, 3:06PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY(R), the only cancer specific, non-PSA blood test to assess the risk for the presence of prostate cancer, throughout the entire United States pursuant to a new co-marketing agreement with Armune BioScience, Inc.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris to Announce First Quarter 2016 Financial and Operating Results on May 9, 2016
BusinessWire - Tue Apr 26, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its first quarter 2016 financial and operating results after market close on Monday, May 9, 2016. The Company will host a conference call and webcast to discuss these results on Tuesday, May 10, 2016 at 8:30 a.m. Eastern Time.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris to Participate in 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities
BusinessWire - Mon Feb 01, 4:33PM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that Chairman, President and Chief Executive Officer David A. Dodd will participate in the 18th Annual BIO CEO & Investor Conference, on February 8 & 9,2016 in New York City. Mr. Dodd will update participants on the status of the Company's two Phase 3 clinical trials and will continue the Company's efforts to secure additional partners for the development of Zoptrex(TM), which if approved by the FDA, would be the first systemic therapy for the treatment of advanced and recurrent endometrial cancer, and for Macrilen(TM), which if approved by the FDA, would be the first orally administered drug indicated for the evaluation of adult growth hormone deficiency ("AGHD". The Company continues to actively seek opportunities to in-license and acquire products for US commercialization, consistent with its goal of becoming a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of its product portfolio.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Announces Appointments to Board of Directors
BusinessWire - Fri Jan 29, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced the appointment of Michael Cardiff and Ken Newport to its Board of Directors, effective immediately, for a term to expire at the Company's upcoming 2016 annual meeting of shareholders, whereupon it is anticipated that each of Messrs. Cardiff and Newport will stand for election as director candidates to be nominated by management.
AEZ.TO: 4.54 (unch), IBM: 156.11 (+0.58), AEZS: 3.49 (+0.02)

Aeterna Zentaris Files International Patent Application for Novel Method of Manufacturing Zoptrex(TM)
BusinessWire - Tue Jan 26, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that it has filed an international patent application as well as national patent applications in selected countries including the US, China, Taiwan, Japan and India. These applications seek to protect the novel method of manufacturing Zoptrex(TM) (zoptarelin doxorubicin), and were filed in addition to a European patent application filed last year. The Company decided to file patent applications in additional territories after the European Patent Office issued a search report for the European patent application that the Company considers to be favorable.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris reports on-market purchases of USD90,000 common stock by executive management
M2 - Tue Jan 26, 3:26AM CST
Biopharmaceutical company Aeterna Zentaris (NASDAQ:AEZS) (TSX:AEZ) said on Monday that certain members of its executive management team have made on-market purchases of an aggregate of 29,535 of its common shares last week at then market prices, representing a total investment of approximately USD90,000.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Aeterna Zentaris Announces Additional Market Purchases of Common Shares by Executive Management
BusinessWire - Mon Jan 25, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZ) (the "Company" today disclosed that it was advised by certain members of its executive management team that such executives made on-market purchases of an aggregate of 29,535 of the Company's Common Shares last week at then market prices, representing a total investment by such executives of approximately $90,000. David A. Dodd, Chairman, President and Chief Executive Officer, purchased 16,300 Common Shares for a total investment of approximately $50,000; Jude Dinges, Senior Vice President and Chief Commercial Officer, purchased 6,500 Common Shares for a total investment of approximately $20,000; and Philip A. Theodore, Senior Vice President, Chief Administrative Officer and General Counsel, purchased 6,735 Common Shares for a total investment of approximately $20,000.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 2.97 (-0.45), TMST: 9.55 (+0.46), CMRX: 5.75 (-0.09), AEZS: 3.49 (+0.02)

Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen(TM)
BusinessWire - Tue Jan 19, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company" announced today that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen(TM) (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD". As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016.
AEZ.TO: 4.54 (unch), AEZS: 3.49 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 71

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 595

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 49

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 103

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 15

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 18

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading

Top 5 Most Recently Viewed Articles

Groundbreaking Grant for Vision Restoration Research at CU

Updated Category News Views 174

Innovative Funding to Restore Vision The University of Colorado Anschutz Medical Campus has secured a significant opportunity—up to $46 million from a federal agency aimed at pioneering research in health. This funding, coming from the Advanced Research Projects Agency for Health (ARPA-H), is intended to propel efforts towards achieving successful whole eye...

Continue Reading
Transocean's Strategic Acquisition: A New Era in Offshore Drilling

Updated Category News Views 279

Transocean Takes a Bold Step in Offshore Drilling Transocean Ltd. has made a definitive move to solidify its leadership position in the offshore drilling landscape. By announcing its acquisition of Valaris Limited in an all-stock deal valued at approximately $5.8 billion, Transocean is not just expanding its operations; it is setting a new benchmark in the energy services...

Continue Reading
Rexford Industrial Realty Sees 5.4% Growth in Q3 2023

Updated Category News Views 64

Rexford Industrial Realty Achieves Impressive Q3 Performance Rexford Industrial Realty, Inc. (NYSE: REXR) reported an impressive 5.4% increase in funds from operations (FFO) per share for the third quarter of 2023, reaching a total of $0.59. This substantial growth demonstrates the company’s ability to navigate the ever-changing market landscape effectively. Alongside...

Continue Reading
Tilray Brands Poised to Share Financial Insights Soon

Updated Category News Views 206

Tilray Brands Preparing for Upcoming Financial Announcement Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a transformative leader in the lifestyle and consumer packaged goods sectors, is set to reveal its financial results for the third quarter of fiscal 2025. This significant update will cover the quarter ending February 28, 2025, and...

Continue Reading
Lam Research Corporation Elevates Dividend to New Heights

Updated Category News Views 98

Lam Research Corporation Elevates Dividend to New Heights Recently, Lam Research Corporation (NASDAQ: LRCX) made a noteworthy announcement regarding its quarterly dividend payments. The company’s Board of Directors approved a 13% increase, raising the dividend from $0.23 to $0.26 per share. This decision underscores the company's commitment to rewarding its shareholders...

Continue Reading